LogicBio Therapeutics (LOGC) to Release Quarterly Earnings on Wednesday

LogicBio Therapeutics (OTCMKTS:LOGC) is expected to announce its Q1 2026 resultson Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.0409) per share for the quarter. Investors can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Friday, May 22, 2026 at 5:00 PM ET.

LogicBio Therapeutics Price Performance

OTCMKTS LOGC opened at $8.74 on Tuesday. The firm has a market cap of $399.16 million, a PE ratio of -8.02 and a beta of 2.10. LogicBio Therapeutics has a one year low of $6.40 and a one year high of $9.14. The stock’s 50 day simple moving average is $8.30 and its 200 day simple moving average is $7.92.

Wall Street Analyst Weigh In

Separately, Wall Street Zen lowered LogicBio Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, March 29th.

Institutional Inflows and Outflows

An institutional investor recently raised its position in LogicBio Therapeutics stock. Goldman Sachs Group Inc. raised its position in LogicBio Therapeutics, Inc. (OTCMKTS:LOGC) by 284.9% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 526,673 shares of the company’s stock after buying an additional 389,843 shares during the period. Goldman Sachs Group Inc. owned about 2.00% of LogicBio Therapeutics worth $3,676,000 as of its most recent filing with the SEC. 46.05% of the stock is owned by hedge funds and other institutional investors.

LogicBio Therapeutics Company Profile

LogicBio Therapeutics, Inc, a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia.